Advanced search
Publication Cover
Pharmacogenomics Volume 14, 2013 - Issue 9
Submit an article Journal homepage
359
Views
0
CrossRef citations to date
0
Altmetric
Review

Germline Pharmacogenetics of Paclitaxel for Cancer Treatment

Daniel L Hertz1 Department of Clinical, Social, & Administrative Sciences, University of Michigan College of Pharmacy, Ann Arbor, MI, USA Tel.: +1 734 763 0015 Fax: +1 734 763 [email protected]View further author information
Pages 1065-1084 | Published online: 09 Jul 2013

References

  • Mielke S , SparreboomA, SteinbergSM et al. Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin. Cancer Res. 11(13) , 4843–4850 (2005).
  • Smith NF , AcharyaMR, DesaiN, FiggWD, SparreboomA. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer. Biol. Ther.4(8) , 815–818 (2005).
  • Sonnichsen D , LiuQ, SchuetzE, SchuetzJ, PappoA, RellingM. Variability in human cytochrome P450 paclitaxel metabolism. J. Pharmacol. Exp. Ther.275(2) , 566–575 (1995).
  • Huisman MT , ChhattaAA, van Tellingen O, Beijnen JH, Schinkel AH. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int. J. Cancer116(5) , 824–829 (2005).
  • Sparreboom A , van Asperen J, Mayer U et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl Acad. Sci. USA94(5) , 2031–2035 (1997).
  • Ioannidis JP , TaroneR, McLaughlinJK. The false-positive to false-negative ratio in epidemiologic studies. Epidemiology22(4) , 450–456 (2011).
  • Lai XS , YangLP, LiXT, LiuJP, ZhouZW, ZhouSF. Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. Curr. Drug Metab.10(9) , 1009–1047 (2009).
  • Hertz DL , WalkoCM, BridgesAS et al. Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure. Br. J. Clin. Pharmacol. 74(1) , 197–200 (2012).
  • The International HapMap Project. Nature426(6968) , 789–796 (2003).
  • Rowbotham SE , BoddyAV, RedfernCPF, VealGJ, DalyAK. Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation. Drug Metab. Dispos.38(8) , 1261–1266 (2010).
  • Gréen H , SöderkvistP, RosenbergP et al. Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic Clin. Pharmacol. Toxicol. 104(2) , 130–137 (2009).
  • Bergmann TK , Brasch-AndersenC, GréenH et al. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J. 11(2) , 113–120 (2011).
  • de Graan AJ , ElensL, SprowlJA et al. CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin. Cancer Res. doi:10.1158/1078-0432.CCR-12-3786 (2013) (Epub ahead of print).
  • Henningsson A , MarshS, LoosWJ et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin. Cancer Res. 11(22) , 8097–8104 (2005).
  • Fransson MN , GréenH, LittonJ, FribergLE. Influence of cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model. Drug Metab. Dispos.39(2) , 247–255 (2011).
  • Marsh S , SomloG, LiX et al. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J. 7(5) , 362–365 (2007).
  • Leskela S , JaraC, Leandro-GarciaL et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J. 11(2) , 121–129 (2011).
  • Hertz DL , RoyS, Motsinger-ReifAA et al. CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann. Oncol.24(6) , 1472–1478 (2013).
  • Marsh S , PaulJ, KingCR, GiffordG, McLeodHL, BrownR. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in ovarian cancer. J. Clin. Oncol.25(29) , 4528–4535 (2007).
  • Ofverholm A , EinbeigiZ, ManouchehrpourS, AlbertssonP, SkrticS, EnerbackC. The ABCB1 3435 T allele does not increase the risk of paclitaxel-induced neurotoxicity. Oncol. Lett.1(1) , 151–154 (2010).
  • Rizzo R , SpaggiariF, IndelliM et al. Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients. Breast Cancer Res. Treat. 124(2) , 593–598 (2010).
  • Bergmann TK , Brasch-AndersenC, GréenH et al. Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer. Basic Clin. Pharmacol. Toxicol. 110(2) , 199–204 (2012).
  • Hertz DL , Motsinger-ReifAA, DrobishA et al. CYP2C8*3 predicts benefit–risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res. Treat.134(1) , 401–410 (2012).
  • Bergmann TK , GréenH, Brasch-AndersenC et al. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur. J. Clin. Pharmacol. 67(7) , 693–700 (2011).
  • Gandara DR , KawaguchiT, CrowleyJ et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J. Clin. Oncol. 27(21) , 3540–3546 (2009).
  • Jiang H , ZhongF, SunL, FengW, HuangZ, TanX. Structural and functional insights into polymorphic enzymes of cytochrome P450 2C8. Amino Acids40(4) , 1195–1204 (2011).
  • Dai D , ZeldinDC, BlaisdellJA et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11(7) , 597–607 (2001).
  • Hichiya H , Tanaka-KagawaT, SoyamaA et al. Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab. Dispos. 33(5) , 630–636 (2005).
  • Saito Y , KatoriN, SoyamaA et al. CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population. Pharmacogenet. Genomics17(7) , 461–471 (2007).
  • Soyama A , SaitoY, HaniokaN et al. Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol. Pharm. Bull. 24(12) , 1427–1430 (2001).
  • Hanioka N , MatsumotoK, SaitoY, NarimatsuS. Functional characterization of CYP2C8.13 and CYP2C8.14: catalytic activities toward paclitaxel. Basic Clin. Pharmacol. Toxicol.107(1) , 565–569 (2010).
  • Rodriguez-Antona C , NiemiM, BackmanJT et al. Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J. 8(4) , 268–277 (2007).
  • Gréen H , KhanMS, Jakobsen-FalkI, Åvall-LundqvistE, PetersonC. Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer. J. Pharm. Sci. doi: 10.1002/jps.22680 (2011) (Epub ahead of print).
  • Wojnowski L , KamdemLK. Clinical implications of CYP3A polymorphisms. Expert Opin. Drug Metab. Toxicol.2(2) , 171–182 (2006).
  • Backman JT , KivistoKT, OlkkolaKT, NeuvonenPJ. The area under the plasma concentration–time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur. J. Clin. Pharmacol.54(1) , 53–58 (1998).
  • Rahmioglu N , HeatonJ, ClementG et al. Genetic epidemiology of induced CYP3A4 activity. Pharmacogenet. Genomics 21(10) , 642–651 (2011).
  • Zhou L , YaoF, LuanH et al. CYP3A4*1B polymorphism and cancer risk: a HuGE review and meta-analysis. Tumor Biol.34(2) , 649–660 (2013).
  • Amirimani B , NingB, DeitzAC, WeberBL, KadlubarFF, RebbeckTR. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ. Mol. Mutagen.42(4) , 299–305 (2003).
  • Rodríguez-Antona C , SayiJG, GustafssonLL, BertilssonL, Ingelman-SundbergM. Phenotype–genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem. Biophys. Res. Commun.338(1) , 299–305 (2005).
  • Wang D , GuoY, WrightonSA, CookeGE, SadeeW. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J.11(4) , 274–286 (2011).
  • Nakajima Y , YoshitaniT, Fukushima-UesakaH et al. Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer. Clin. Pharmacol. Ther. 80(2) , 179–191 (2006).
  • Maekawa K , HarakawaN, YoshimuraT et al. CYP3A4*16 and CYP3A4*18 alleles found in east Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs. Drug Metab. Dispos.38(12) , 2100–2104 (2010).
  • Nakajima M , FujikiY, KyoS et al. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J. Clin. Pharmacol. 45(6) , 674–682 (2005).
  • Kuehl P , ZhangJ, LinY et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4) , 383–391 (2001).
  • Baker SD , VerweijJ, CusatisGA et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin. Pharmacol. Ther. 85(2) , 155–163 (2008).
  • Ieiri I . Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug Metab. Pharmacokinet.27(1) , 85–105 (2012).
  • Chang H , RhaSY, JeungHC et al. Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy. Oncol. Rep. 23(1) , 271–278 (2010).
  • Chang H , RhaSY, JeungHC et al. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann. Oncol. 20(2) , 272–277 (2009).
  • Hemauer SJ , NanovskayaTN, Abdel-RahmanSZ, PatrikeevaSL, HankinsGDV, AhmedMS. Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms. Biochem. Pharmacol.79(6) , 921–925 (2010).
  • Jiko M , YanoI, SatoE et al. Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. Int. J. Clin. Oncol. 12(4) , 284–290 (2007).
  • Yamaguchi H , HishinumaT, EndoN et al. Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer. Int. J. Gynecol. Cancer 16(3) , 979–985 (2006).
  • Grau JJ , CaballeroM, CampayoM et al. Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel. Laryngoscope 119(8) , 1484–1490 (2009).
  • Johnatty SE , BeesleyJ, PaulJ et al. ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin. Cancer Res.14(17) , 5594–5601 (2008).
  • Shitara K , MatsuoK, ItoS et al. Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy. Asian Pac. J. Cancer. Prev. 11(2) , 447–452 (2010).
  • Sissung TM , MrossK, SteinbergSM et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur. J. Cancer 42(17) , 2893–2896 (2006).
  • Gow JM , HodgesLM, ChinnLW, KroetzDL. Substrate-dependent effects of human ABCB1 coding polymorphisms. J. Pharmacol. Exp. Ther.325(2) , 435–442 (2008).
  • Kwon WS , RhaSY, JeungH et al. G–T haplotype (2677G>T/A and 3435C>T) of ABCB1 gene polymorphisms is associated with ethnic differences to paclitaxel sensitivity in cancer cells with different gene expression pattern. Cancer Lett. 277(2) , 155–163 (2009).
  • Gréen H , SoderkvistP, RosenbergP, HorvathG, PetersonC. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin. Cancer Res.12(3) , 854–859 (2006).
  • Marsh S , KingCR, McLeodHL, PaulJ, GiffordG, BrownR. ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer. Clin. Cancer Res.12(13) , 4127–4129 (2006).
  • Kim JW , KimJH, ImSA et al. ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy. Oncology83(4) , 218–227 (2012).
  • Ludwig AH , KupryjañczykJ. Does MDR-1 G2677T/A polymorphism really associate with ovarian cancer response to paclitaxel chemotherapy? Clin. Cancer Res.12(20) , 6204–6204 (2006).
  • Kim HS , KimM, ChungHH et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol. Oncol. 113(2) , 264–269 (2009).
  • Crouthamel MH , WuD, YangZ, HoRJY. A novel MDR1 G1199T variant alters drug resistance and efflux transport activity of P-glycoprotein in recombinant Hek cells. J. Pharm. Sci.95(12) , 2767–2777 (2006).
  • Gréen H , SöderkvistP, RosenbergP, HorvathG, PetersonC. ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel. J. Pharm. Sci.97(6) , 2045–2048 (2008).
  • Takane H , KobayashiD, HirotaT et al. Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene. J. Pharmacol. Exp. Ther. 311(3) , 1179–1187 (2004).
  • Ieiri I , HiguchiS, SugiyamaY. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin. Drug Metab. Toxicol.5(7) , 703–729 (2009).
  • Lagas JS , VlamingML, van Tellingen O et al. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin. Cancer Res.12(20) , 6125–6132 (2006).
  • Sun N , SunX, ChenB et al. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother. Pharmacol.65(3) , 437–446 (2010).
  • van de Steeg E , van Esch A, Wagenaar E et al. High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel. Clin. Cancer Res.17(2) , 294–301 (2011).
  • Takano M , OtaniY, TandaM, KawamiM, NagaiJ, YumotoR. Paclitaxel-resistance conferred by altered expression of efflux and influx transporters for paclitaxel in the human hepatoma cell line, HepG2. Drug Metab. Pharmacokinet.24(5) , 418–427 (2009).
  • Smith NF , MarshS, Scott-HortonTJ et al. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin. Pharmacol. Ther. 81(1) , 76–82 (2007).
  • Burckhardt G , BurckhardtBC. In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy. Handb. Exp. Pharmacol. (201) , 29–104 (2011).
  • Tian C , AmbrosoneCB, DarcyKM et al. Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a gynecologic oncology group study. Gynecol. Oncol. 124(3) , 575–581 (2012).
  • Hasmats J , KupershmidtI, Rodríguez-AntonaC et al. Identification of candidate SNPs for drug induced toxicity from differentially expressed genes in associated tissues. Gene 506(1) , 62–68 (2012).
  • Chen Y , TangY, GuoC, WangJ, BoralD, NieD. Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem. Pharmacol.83(8) , 1112–1126 (2012).
  • Lim YP , LiuCH, ShyuLJ, HuangJD. Functional characterization of a novel polymorphism of pregnane X receptor, Q158K, in Chinese subjects. Pharmacogenet. Genomics15(5) , 337–341 (2005).
  • Saeki M , KuroseK, HasegawaR, TohkinM. Functional analysis of genetic variations in the 5´-flanking region of the human MDR1 gene. Mol. Genet. Metab.102(1) , 91–98 (2011).
  • Berrieman HK , LindMJ, CawkwellL. Do β-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol.5(3) , 158–164 (2004).
  • Leandro-Garcia LJ , LeskelaS, Jara Sanchez C et al. Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy. Clin. Cancer Res.18(16) , 4441–4448 (2012).
  • Leandro-García LJ , LeskeläS, Inglada-PérezL et al. Hematologic β-tubulin VI isoform exhibits genetic variability that influences paclitaxel toxicity. Cancer Res. 72(18) , 4744–4752 (2012).
  • Gajjar K , Martin-HirschPL, MartinFL. CYP1B1 and hormone-induced cancer. Cancer Lett.324(1) , 13–30 (2012).
  • Bournique B , LemariéA. Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme. Drug Metab. Dispos.30(11) , 1149–1152 (2002).
  • Pastina I , GiovannettiE, ChioniA et al. Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in castration-resistant prostate cancer (CRPC) patients. BMC Cancer 10 , 511 (2010).
  • Figg WD , LiH, SissungT et al. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int. 99(5) , 1047–1055 (2007).
  • Sissung TM , DanesiR, PriceDK et al. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol. Cancer Ther. 7(1) , 19–26 (2008).
  • Sucheston L , ZhaoH, YaoS et al. Genetic predictors of taxane-induced neurotoxicity in a SWOG Phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res. Treat. 130(3) , 993–1002 (2011).
  • Sato Y , YamamotoN, KunitohH et al. Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel. J. Thorac. Oncol. 6(1) , 132–138 (2011).
  • Schneider BP , LiL, MillerK et al. Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. ASCO Meeting Abstracts 29(15 Suppl.) , S1000 (2011).
  • Bergmann TK , VachW, FeddersenS et al. GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients. Acta Oncol. 52(4) , 871–874 (2012).
  • Baldwin RM , OwzarK, ZembutsuH et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin. Cancer Res. 18(18) , 5099–5109 (2012).
  • Delague V , JacquierA, HamadoucheT et al. Mutations in FGD4 encoding the Rho GDP/GTP exchange factor FRABIN cause autosomal recessive Charcot–Marie–Tooth type 4H. Am. J. Hum. Genet. 81(1) , 1–16 (2007).
  • Wheeler HE , GamazonER, WingC et al. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of paclitaxel-induced sensory peripheral neuropathy. Clin. Cancer Res. 19(2) , 491–499 (2012).
  • Njiaju UO , GamazonER, GorsicLK et al. Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel. Pharmacogenet. Genomics 22(7) , 498–507 (2012).
  • O‘Brien C , CavetG, PanditaA et al. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res. 68(13) , 5380–5389 (2008).
  • Niu N , SchaidD, AboR et al. Genetic association with overall survival of taxane-treated lung cancer patients – a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study. BMC Cancer 12(1) , 422 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.